Investing.com -- Shares in Sanofi (EPA:SASY) (NASDAQ:SNY) and Regeneron (NASDAQ:REGN) fell Friday after the pharmaceutical giants reported mixed results from two phase 3 trials of their ...

Investing.com -- Shares in Sanofi (EPA:SASY) (NASDAQ:SNY) and Regeneron (NASDAQ:REGN) fell Friday after the pharmaceutical giants reported mixed results from two phase 3 trials of their ...

Sanofi and Regeneron said that drug candidate Itepekimab met the primary goal in one of two chronic obstructive pulmonary disease phase 3 studies, but didn't hit the main objective of a second ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Regeneron Pharmaceuticals and Sanofi announced that their Phase 3 clinical trial, AERIFY-1, showed a significant 27% reduction in moderate to severe exacerbations of COPD in former smokers treated ...

Sanofi’s U.S.-listed shares plunged more than 6% by 09:50 GMT, while Regeneron plummeted over 18%. Advertisement: High Yield Savings Offers Earn 4.10% APY** on balances of $5,000 or more ...

You can reach Andrew on Signal at drewqjoseph.45. An experimental COPD medicine from Sanofi and Regeneron Pharmaceuticals produced mixed results in a pair of studies, the companies said Friday ...

Sanofi is harnessing the power of pop music to boost awareness of the experience of living with Type 1 diabetes. The French drugmaker has sponsored the formation of a new girl group, dubbed 1Type ...

Recent research from Sanofi highlights the significant impact of Type 1 Diabetes on those living with the condition The song, "Rise Up," shares their experiences of living with the condition and ...

The U.S. Food and Drug Administration (FDA) has approved Sanofi’s (NASDAQ:SNY) meningococcal vaccine MenQuadfi for infants as young as six weeks, expanding its previous label indicated for ...

The U.S. Food and Drug Administration (FDA) has approved Sanofi’s (NASDAQ:SNY) meningococcal vaccine MenQuadfi for infants as young as six weeks, expanding its previous label indicated for children ...